International Stem Cell Corp. (ISCO)

Take a look at some of our previously featured companies

International Stem Cell Corp. (ISCO)

Postby QualityStocks » Fri May 11, 2012 7:21 am

International Stem Cell Corp. specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Video Charts http://Videocharts.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please see our Profile for Disclaimers
QualityStocks
Site Admin
 
Posts: 9170
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: International Stem Cell Corp. (ISCO)

Postby QualityStocks » Fri May 11, 2012 7:21 am

International Stem Cell Corp. (ISCO) Announces New Stem Cell Manufacturing Technologies

International Stem Cell Corp., developer of therapeutic applications of human parthenogenetic stem cells (hpSCs) and cell-based research and cosmetic products, announced today that they have developed new technologies to commercialize the use of human parthenogenetic stem cells to treat human diseases. The methods announced are able to produce populations of stem cells, in addition to their therapeutically valuable derivatives, at a higher level of purity and at a cost that is several times lower than previously reported techniques.

Specifically, the company’s research team has developed a new method of generating high-purity populations of neural stem cells from hpSC, and then further differentiating them into dopaminergic neurons. The method is able to produce sufficient quantities of neuronal cells for the company’s pre-clinical and clinical studies. Moreover, it requires substantially less time and labor and uses fewer costly materials than traditional methods. It means that the billions of neuronal cells needed for conducting such studies can now be produced from a small batch of stem cells.

In addition, ISCO has developed a new high-throughput cell culture method for growing human parthenogenetic stem cells in large quantities, a method that is easily scalable and can produce the quantities of cGMP grade hpSC required for commercial and therapeutic applications.

ISCO VP of R&D, Dr. Ruslan Semechkin, said of the new developments: “One of the most challenging issues in commercializing stem cell based treatments is creating high-purity populations of stem cell derivatives at a reasonable cost. I believe the new methods we have developed solve this important problem and help position us for future clinical studies”.

ISCO’s core technology is parthenogenesis, which can create pluripotent human stem cells from unfertilized oocytes (eggs), thereby avoiding the ethical issues associated with the use or destruction of viable human embryos. The company produced the first parthenogenic homozygous stem cell line, a potential source of therapeutic cells for hundreds of millions of individuals of differing genders, ages, and racial background, with minimal immune rejection after transplantation. Such parthenogenetic stem cells could be the bases for the first true human stem cell bank, UniStemCellTM. The company also produces and markets specialized cells and growth media for therapeutic research through its Lifeline Cell Technology subsidiary, as well as stem cell-based skin care products through its Lifeline Skin Care subsidiary.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Video Charts http://Videocharts.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please see our Profile for Disclaimers
QualityStocks
Site Admin
 
Posts: 9170
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: International Stem Cell Corp. (ISCO)

Postby protostars » Fri May 11, 2012 8:00 am

As with so many newly developed biotechnologies, the ability to produce in scalable quantities becomes a critical factor, and ISCO holds a key to this.
Please see profile for disclaimer
protostars
 
Posts: 10746
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: International Stem Cell Corp. (ISCO)

Postby stockseeker30 » Fri May 11, 2012 9:37 pm

Very true, ICSO has found a way to mass produce their product without the negative attention.This is one to keep an eye on.
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 8199
Joined: Sat Aug 21, 2010 9:02 pm

Re: International Stem Cell Corp. (ISCO)

Postby mwest » Fri May 11, 2012 10:37 pm

Being able to be conscience enough to create a method without the controversy is great, it will allow both sides to have a viable option so not to hinder research in an area that's needed.
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 10383
Joined: Thu Apr 09, 2009 3:09 pm

Re: International Stem Cell Corp. (ISCO)

Postby protostars » Mon May 14, 2012 8:05 am

On the cosmetic side, their Lifeline® Skin Care subsidiary offers the only skin care line that is based on human parthenogenetic stem cells, which stimulate your skin’s own abilities to repair itself. Unsure exactly how this works.
Please see profile for disclaimer
protostars
 
Posts: 10746
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: International Stem Cell Corp. (ISCO)

Postby QualityStocks » Mon May 14, 2012 9:38 am

International Stem Cell Corp. (ISCO) Video Chart for Monday, May 14, 2012

ISCO has formed a triple bottom pattern with support at 40 cents. There is more support down at 34 cents, but the 40 cent mark has produced two bounces in excess of 50 percent (to $0.68 and $0.65) in the last five months. Technical traders will be watching closely for the pattern to repeat.

To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Video Charts http://Videocharts.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please see our Profile for Disclaimers
QualityStocks
Site Admin
 
Posts: 9170
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: International Stem Cell Corp. (ISCO)

Postby armedical » Mon May 14, 2012 6:42 pm

This gives the impression that buying in now would be a good move.
I am not a registered investment advisor. Invest at your own risk. See profile for disclaimer.
armedical
 
Posts: 3136
Joined: Mon Aug 30, 2010 11:30 am

Re: International Stem Cell Corp. (ISCO)

Postby mwest » Mon May 14, 2012 9:51 pm

I agree the writing is there for investors to see clearly.
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 10383
Joined: Thu Apr 09, 2009 3:09 pm

Re: International Stem Cell Corp. (ISCO)

Postby stockseeker30 » Mon May 14, 2012 9:59 pm

As long as they continue to supply products like Anti-aging creme, the audience will always be there.
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 8199
Joined: Sat Aug 21, 2010 9:02 pm

Re: International Stem Cell Corp. (ISCO)

Postby protostars » Tue May 15, 2012 6:40 am

Don't know how stem cell technology works with their cosmetic side, but stem cell production technology is a big deal.
Please see profile for disclaimer
protostars
 
Posts: 10746
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: International Stem Cell Corp. (ISCO)

Postby armedical » Tue May 15, 2012 7:23 am

As they said ok thee press release the market is out there for products that are produced off stem cells but the key is producing these without controversy.
I am not a registered investment advisor. Invest at your own risk. See profile for disclaimer.
armedical
 
Posts: 3136
Joined: Mon Aug 30, 2010 11:30 am

Re: International Stem Cell Corp. (ISCO)

Postby QualityStocks » Tue May 15, 2012 8:35 am

International Stem Cell Corp. (ISCO) Scientists to Attend Gene and Cell Therapy Meeting in Philadelphia and Present Pre-Clinical Research Results

International Stem Cell Corp. this morning announced that several of its leading scientists will be presenting experimental results from three of ISCO’s pre-clinical therapeutic programs at the 15th Annual Meeting of American Society of Gene and Cell Therapy, in Philadelphia at 3:30 p.m. on Thursday, May 17th.

Firstly, the application of A9 dopaminergic neurons derived from human parthenogenetic stem cells (hpSC) for the treatment of Parkinson’s disease. Demonstrating functional dopaminergic neurons in vivo represents an important milestone towards the goal of creating well characterized populations of cells that could be used to develop a treatment for Parkinson’s.

Secondly, the differentiation of hpSC and embryonic stem cells into cornea-like constructs for use in transplantation therapy and the in vitro study of ocular drug absorption. There are approximately ten million people worldwide who are blind as a result of damage to their cornea. Generating human corneas from a pluripotent stem cell source should increase the likelihood that people will receive treatment in the future even in the absence of suitable tissue from eye banks.

Lastly, the in vivo and in vitro characterization of immature hepatocyte derived from hpSC. Such cells could be used to develop a treatment for individuals with a liver that has been damaged by disease or sufferers of genetic disorders that inhibit normal liver function. In both cases, implanting healthy hepatocyte cells could treat the underlying disease and prolong the life of the individual.

“These results not only show the progress we have made in these important programs, but also demonstrate the broad application of human parthenogenetic stem cells in the development of treatments for incurable diseases,” stated Dr. Ruslan Semechkin, Vice President of Research and Development.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Video Charts http://Videocharts.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please see our Profile for Disclaimers
QualityStocks
Site Admin
 
Posts: 9170
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: International Stem Cell Corp. (ISCO)

Postby mwest » Tue May 15, 2012 3:56 pm

Receiving help with blindness would be an amazing feat for ISCO to make
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 10383
Joined: Thu Apr 09, 2009 3:09 pm

Re: International Stem Cell Corp. (ISCO)

Postby stockseeker30 » Tue May 15, 2012 9:40 pm

Many discussions have been made on this topic for sure
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 8199
Joined: Sat Aug 21, 2010 9:02 pm

Re: International Stem Cell Corp. (ISCO)

Postby protostars » Wed May 16, 2012 6:58 am

All part of their continuing campaign to bring parthenogenetic stem cells to the marketplace.
Please see profile for disclaimer
protostars
 
Posts: 10746
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: International Stem Cell Corp. (ISCO)

Postby QualityStocks » Wed May 16, 2012 8:31 am

International Stem Cell Corp. (ISCO) Reports Q1 2012 Financial Results and Business Highlights

Today before the opening bell, International Stem Cell Corporation announced its financial results for the three months ended March 31, 2012.

Consolidated net revenues for the period were $1.08 million compared to $1.52 million a year earlier. The year-over-year decrease in revenues is due to fewer sales generated from the Lifeline Skin Care (LSC) direct sales channel, partially offset by higher Lifeline Cell Technology (LCT) sales generated from larger distributors. LSC and LCT accounted for 51% and 49% of total revenue in the three months ended March 31, 2012 compared to 75% and 25%, respectively, in the comparable period a year ago.

For the three months ended March 31, 2012, development expenses were $3.80 million, representing a decrease of approximately 5% compared to the corresponding period in 2011. The decrease primarily reflects lower general and administrative expenses resulting from decreased stock-based compensation expense and lower laboratory-related expenses. The decrease was partially offset by higher cost of sales ratio resulting from increased sales concentration of lower margin products, and higher marketing and selling expense related to LSC. The Company continued to invest in its sales and marketing infrastructure, including significant enhancements to the e-commerce platforms, increased advertising and strengthening the sales and customer service organization.

Cash and cash equivalents at March 31, 2012 were $6.01 million compared to $1.34 million at December 31, 2011, reflecting an increase of $4.67 million resulting from two financing transactions including the issuance of shares of Series G preferred stock for $5.00 million and issuance of shares of common stock for a total of $2.08 million in the first quarter of 2012.

The company continued to focus its research and development efforts on the creation of additional parthenogenetic stem cell lines for therapeutic use and on the advancement of the disease area research programs, particularly pre-clinical in vivo safety and efficacy studies in Parkinson’s disease and new methods for high-throughput cell culture and stem cell differentiation.

ISCO’s wholly-owned subsidiary Lifeline Skin Care drove sales by expanding acquisition of both retail and trade customers, increasing the average order value and enhancing customer loyalty and retention. New retail customers were attracted by an increased social media presence and national exposure on TV shows such as ABC’s “The Talk” and the use of risk-free introductory offers and free sample promotions. In addition, LSC continued to increase the number of strategic marketing partnerships. Although LSC revenue for the quarter was lower than the same period in 2011, the sales were generated from more diversified sources with much greater growth potential and reduced reliance on individual third parties.

Lifeline Cell Technology, ISCO’s wholly-owned subsidiary specialized in cells and media research products, grew revenue across all three sales channels including domestic, international, and OEM, showing a 39% increase over the same quarter of 2011.

The overall financial position of the company was significantly improved. ISCO increased its liquidity by securing a total $7.03 million of capital through equity financing transactions in the first quarter of 2012.

Dr. Andrey Semechkin, ISCO’s CEO and Co-Chairman, commented, “The first quarter of this year has been a challenging one for ISCO. However, with the significant improvement of our balance sheet position resulting from the closing of the financings, coupled with the addition of Dr. Berglund as a new independent director to our Board of Directors, I believe that we have strengthened our foundation on which we can increase our competitiveness.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Video Charts http://Videocharts.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please see our Profile for Disclaimers
QualityStocks
Site Admin
 
Posts: 9170
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: International Stem Cell Corp. (ISCO)

Postby armedical » Wed May 16, 2012 8:08 pm

It's good to see that overall financial state of the company was good and that despite some set backs they are looking toward the future with optimism.
I am not a registered investment advisor. Invest at your own risk. See profile for disclaimer.
armedical
 
Posts: 3136
Joined: Mon Aug 30, 2010 11:30 am

Re: International Stem Cell Corp. (ISCO)

Postby mwest » Wed May 16, 2012 9:50 pm

a 4.67 million dollar increase in cash for ISCO over last year, that is truely an amazing number.
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 10383
Joined: Thu Apr 09, 2009 3:09 pm

Re: International Stem Cell Corp. (ISCO)

Postby stockseeker30 » Wed May 16, 2012 9:53 pm

As they mentioned this has helped them strengthen there foundation.
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 8199
Joined: Sat Aug 21, 2010 9:02 pm

Next

Return to QualityStocks Previous Clients

Who is online

Users browsing this forum: No registered users and 2 guests

cron